ADD abstract
This commit is contained in:
parent
50e03ef8a4
commit
17aaa53dde
|
@ -1,9 +1,13 @@
|
|||
*
|
||||
!tex
|
||||
tex/*
|
||||
!tex/*.tex
|
||||
!tex/*.bib
|
||||
!tex/*.glo
|
||||
!thesis
|
||||
thesis/*
|
||||
!thesis/*.tex
|
||||
!thesis/*.bib
|
||||
!thesis/*.glo
|
||||
|
||||
!abstract
|
||||
abstract/*
|
||||
!abstract/*.tex
|
||||
|
||||
!figures
|
||||
figures/*
|
||||
|
|
|
@ -0,0 +1,57 @@
|
|||
\documentclass{article}
|
||||
\usepackage[top=1in,left=1in,right=1in,bottom=1in]{geometry}
|
||||
\usepackage{setspace}
|
||||
|
||||
\pagestyle{empty}
|
||||
|
||||
\begin{document}
|
||||
|
||||
\begin{center}
|
||||
\LARGE{\textbf{Optimizing T Cell Manufacturing and Quality Using
|
||||
Functionalized Degradable Microscaffolds}}
|
||||
|
||||
\Large
|
||||
|
||||
\bigskip
|
||||
|
||||
Nathan J. Dwarshuis
|
||||
|
||||
\bigskip
|
||||
|
||||
165 pages
|
||||
|
||||
\bigskip
|
||||
|
||||
Directed by Krishnendu Roy
|
||||
\end{center}
|
||||
|
||||
\large
|
||||
|
||||
\doublespacing{}
|
||||
|
||||
Adoptive cell therapy using chimeric antigen receptor (CAR) T cells have shown
|
||||
promise in treating cancer, but manufacturing large numbers of high quality
|
||||
cells remains challenging. Currently approved T cell expansion technologies
|
||||
involve anti-CD3 and anti-CD28 antibodies, usually mounted on magnetic beads.
|
||||
This method fails to recapitulate many key signals found \textit{in vivo} and is
|
||||
also heavily licensed by a few companies, limiting its long-term usefulness to
|
||||
manufactures and clinicians. Furthermore, highly potent, anti-tumor T cells are
|
||||
generally less-differentiated subtypes such as central memory and stem memory T
|
||||
cells. Despite this understanding, little has been done to optimize T cell
|
||||
expansion for generating these subtypes, including measurement and feedback
|
||||
control strategies that are necessary for any modern manufacturing process.
|
||||
|
||||
The goal of this dissertation was to develop a microcarrier-based degradable
|
||||
microscaffold (DMS) T cell expansion system and determine
|
||||
biologically-meaningful critical quality attitudes and critical process
|
||||
parameters that could be used to optimize for highly-potent T cells. We
|
||||
developed and characterized the DMS system, including quality control steps. We
|
||||
also demonstrated the feasibility of expanding high-quality T cells. We used
|
||||
Design of Experiments methodology to optimize the DMS platform, and we developed
|
||||
a computational pipeline to identify and model the effects of measurable
|
||||
critical quality attributes and critical process parameters on the final
|
||||
product. Finally, we demonstrated the effectiveness of the DMS platform
|
||||
\textit{in vivo}. This thesis lays the groundwork for a novel T cell expansion
|
||||
method which can be utilized at scale for clinical trials and beyond.
|
||||
|
||||
\end{document}
|
|
@ -1,6 +1,6 @@
|
|||
\documentclass{report}
|
||||
\usepackage[section]{placeins}
|
||||
\usepackage[top=1in,left=1.5in,right=1in,bottom=1in]{geometry}
|
||||
\usepackage[section]{placeins}
|
||||
\usepackage{siunitx}
|
||||
\usepackage{multicol}
|
||||
\setlength{\columnsep}{1cm}
|
Loading…
Reference in New Issue